Donor Eligibility/Cell testing Service

 

Category: Cell Therapy and Regenerative Medicine

Exhibitor: MITEKLAB CO., LTD.

Booth No: M618

 

Characteristic

 

Driven by the advancement of the Regenerative Medicinal Act, many biotechnology companies have actively engaged in the development of Allogeneic cell therapies. Compared to Autologous, Allogeneic therapies require more strict control over cell sourcing, quality, and regulatory compliance, resulting in higher development costs and longer timelines.

As a result, the development strategies often directly start with a ''Global Market'' as the target, utilizing standardized processes to scale up cell production maximally in order to create greater commercial value.

Key processing include:
▪ Donor Eligibility/Screening
▪ Master Cell Bank (MCB)/Working Cell Bank (WCB)
▪ Final Product Release Testing

Mitek has a professional team dedicated to providing customized management solutions, including clinical site training, coordination of domestic and international testing, as well as sample export and logistics handling. We offer a comprehensive, localized, one-stop service to support the efficient advancement of your cell therapy project！！！

 

Other Products

 

• 

  ARES™ X20+ Fill & Finish System

• 

  Cedex

• 

  mRNA

• 

  SCREEN NX

• 

  Healthy Primary Cells from Peripheral Blood, Bone Marrow, and Cord Blood

• 

  cGMP Grade Human Male AB PD Serum

• 

  Human Biospecimen Suppliers

• 

  Molecular standards

• 

  Advanced Fluid Management solutions in Biopharma

 

 

 

Back